EPIX News and Press, ESSA Pharma Inc. From 10/26/23

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat Canada NewsWire Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in pat...

2023-10-24 11:23:00 ET Summary Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting a buying opportunity. The company's technology for next-generation ADCs has shown safety benefits a...

2023-10-23 10:00:15 ET Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in For further details see: ImmunityBio, Palatin Technologies among healthcare movers

2023-10-23 08:31:36 ET Losers: Revolution Medicines ( RVMD ) -31% . Troika Media Group ( TRKA ) -21% . Li-Cycle Holdings Corp ( LICY ) -21% announces review of the rochester hub project . Mmtec ( MTC ) -18% . Palatin Technologies ( ...

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress Canada NewsWire Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients w...

2023-10-16 08:30:08 ET PCTEL  ( NASDAQ: PCTI ) +48% . Essa Pharma  ( EPIX ) +32% . Almacenes Exito ( EXTO ) +32% . Ambrx Biopharma  ( AMAM ) +32% Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX5...

2023-09-19 17:05:50 ET More on ESSA Pharma Seeking Alpha’s Quant Rating on ESSA Pharma Historical earnings data for ESSA Pharma Financial information for ESSA Pharma For further details see: ESSA Pharma files for $200M mixed shelf offering - filing

ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Canada NewsWire Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined w...

2023-08-08 08:00:21 ET ESSA Pharma press release ( NASDAQ: EPIX ): Q2 GAAP EPS of -$0.17 beats by $0.03 . At June 30, 2023, the Company had available cash reserves and short-term investments of $152.5 million reflecting the gross proceeds of the February 2021 fina...

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023 Canada NewsWire Completion of the Phase 1 EPI-7386 combination study with Xtandi ® (enzalutamide) expected in the third calendar quarter of 202...